In focus channel feed

Ahead of FDA com­mit­tee to dis­cuss new ALS drug, the ju­ry re­mains out on how much ben­e­fit is enough for ap­proval

8 months ago
R&D
FDA+

Covid vac­cines and drugs are free. But for many im­muno­com­pro­mised pa­tients, pro­tec­tion comes at a cost

8 months ago
Coronavirus

Bio­phar­ma has hyped AI for years. But as the first tri­als get un­der­way, ex­perts try to man­age ex­pec­ta­tions

9 months ago
AI

Small biotechs with big drug am­bi­tions threat­en to up­end the tra­di­tion­al drug launch play­book

10 months ago
Marketing

A new can­cer im­munother­a­py brings cau­tious hope for a field long await­ing the next big break­through

10 months ago
R&D

How a tiny Swiss lab and two old blood sam­ples cre­at­ed one of the on­ly ef­fec­tive drugs against Omi­cron (and why we have so lit­tle of it)

11 months ago
Coronavirus

In­side the multi­bil­lion-dol­lar, Sil­i­con Val­ley-backed ef­fort to reimag­ine how the world funds (and con­ducts) sci­ence

11 months ago
Discovery

‘Dis­ap­point­ing’ Vi­a­Cyte da­ta raise ques­tions about fu­ture of com­pa­ny’s at­tempt­ed di­a­betes cure

11 months ago
R&D
Cell/Gene Tx

EQRx wants to turn drug pric­ing re­form on its head. Can it suc­ceed, or will Big Phar­ma stop it in its tracks?

11 months ago
Pharma

A new an­ti­body treat­ment of­fers long-await­ed hope for im­muno­com­pro­mised pa­tients, if Omi­cron does­n't get here first

11 months ago
Coronavirus

Omi­cron is a test for the next pan­dem­ic. Will the world keep mak­ing the same mis­takes?

Last year
Coronavirus

Ex­clu­sive: Big-name aca­d­e­mics and in­vestors are qui­et­ly prepar­ing a slate of new (epi)genome edit­ing com­pa­nies

Last year
Cell/Gene Tx

‘It’s a trans­for­ma­tion’: Re­searchers are tak­ing Deep­Mind’s ground­break­ing pro­tein fold­ing soft­ware to places few pre­dict­ed

Last year
Discovery

They had promis­ing gene ther­a­pies for their daugh­ter's ul­tra-rare dis­ease. But how to tell if one worked?

Last year
Cell/Gene Tx

An­ti­sense tech­nol­o­gy changed one dev­as­tat­ing dis­ease. Why has­n't it trans­formed oth­ers?

Last year
R&D

How Chi­na turned the ta­bles on bio­phar­ma's glob­al deal­mak­ing

Last year
China

Con­tract re­search is hav­ing a mo­ment right now. Will M&A splash­es dri­ve the in­dus­try to even greater heights?

Last year
Outsourcing

The coro­n­avirus vac­cine that the world for­got could still help save it

Last year
Coronavirus

As Bay­er, No­var­tis stack up their ra­dio­phar­ma­ceu­ti­cal da­ta at #ES­MO21, a key de­bate takes shape

Last year
R&D

In­side the quixot­ic 30-year quest that gave us the Covid-19 treat­ments, vac­cines and could un­lock vac­ci­nol­o­gy’s new holy grail

Last year

'The con­sum­mate men­tor': Bill Clin­ton, Jim Wil­son and oth­ers re­flect on Tachi Ya­mada's life and lega­cy

Last year
People

In Cure­Vac's fail­ure, a pos­si­ble ver­dict on the past (and fu­ture) of mR­NA vac­cines

Last year
R&D

How one start­up fore­told the neu­ro­science re­nais­sance af­ter '50 years of shit­show'

Last year
R&D

On the hunt for the next Mod­er­na, in­vestors have pumped 'plat­form plays' with cash. Can any­thing slow the run­away train?

Last year
Financing
First page Previous page 1234 Next page Last page